Breast Cancer Mortality Rates Down

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

WASHINGTON--The breast cancer death rate in American women has declined steadily in the 1990s, suggesting that improved breast cancer management from early detection to treatment is having a beneficial effect, the National Cancer Institute reports.

WASHINGTON--The breast cancer death rate in American women hasdeclined steadily in the 1990s, suggesting that improved breastcancer management from early detection to treatment is havinga beneficial effect, the National Cancer Institute reports.

From 1989 to 1993, age-adjusted mortality rates fell approximately6% in white women and rose about 1% in black women. This is animprovement over 1980 to 1989, when rates increased by 3% in whitewomen and 16% in black women.

The report attributed the decline in mortality only partly tomammography screening, stating that "further study is requiredto determine the relative contribution of early detection andimproved treatment."

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content